Montauk Renewables (MNTK) Q1 2025 earnings summary

Executive summary

• First quarter 2025 revenues rose 9.8% year-over-year to $42.6 million, but net loss was $0.5 million, down from net income of $1.9 million in Q1 2024, due to lower realized RIN pricing, higher operating expenses, and a $2.0 million impairment related to Blue Granite RNG.

• RNG production volumes were flat at 1.4 million MMBtu, while RINs sold increased 25.3% year-over-year, driven by regulatory changes and inventory management.

• Average realized RIN price fell 24.3% to $2.46, impacting revenue and profitability.

• Major development projects, including North Carolina swine waste-to-energy, Second Apex RNG Facility, and Rumpke relocation, are advancing, with significant capital expenditures planned.

• Regulatory delays and EPA rule changes affected RIN sales timing and market dynamics, but all 2024 D3 RINs were sold, eliminating exposure to compliance waiver timing.

Financial highlights

• Operating income fell to $0.4 million from $2.4 million in Q1 2024, an 82.7% decrease.

• Adjusted EBITDA was $8.8 million, down 7.2% from $9.5 million in Q1 2024.

• Cash and cash equivalents at quarter-end were $40.1 million; net cash from operating activities was $9.1 million, down from $14.3 million in Q1 2024.

• Capital expenditures totaled $11.6 million, mainly for Montauk Ag Renewables, Apex, and Bowerman projects.

• General and administrative expenses decreased 7.1% to $8.8 million.

Outlook and guidance

• 2025 RNG production expected between 5.8–6.0 million MMBtu, with revenues of $150–$170 million.

• Renewable electricity production forecasted at 178,000–186,000 MWh, with revenues of $17–$18 million.

• Major capital projects include Rumpke relocation (capex $80–$110 million), Second Apex RNG Facility, and biogenic CO2 contract with European Energy North America.

• Management expects sufficient liquidity from operations and credit facility to fund growth initiatives over the next 12–24 months.

• Full-year 2025 outlook reaffirmed despite regulatory uncertainty.